COMMUNIQUÉS West-GlobeNewswire

-
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
25/01/2024 -
Cronos’ Spinach® Brand Ends 2023 as the Number One Flower Brand in Canada1
25/01/2024 -
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
25/01/2024 -
Embrace the Taste of Paradise with Breckenridge Brewery’s Refreshing New ‘Juicy Oasis Fruited Hazy IPA’
25/01/2024 -
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25/01/2024 -
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
25/01/2024 -
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25/01/2024 -
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
25/01/2024 -
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25/01/2024 -
Le KFSH&RC honore 25 scientifiques nommés dans le classement de Stanford parmi les 2 % des chercheurs les plus cités au monde
25/01/2024 -
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25/01/2024 -
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
25/01/2024 -
Nicox : Résumé financier et point d’activité du quatrième trimestre 2023
25/01/2024 -
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
25/01/2024 -
BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
25/01/2024 -
AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device
25/01/2024 -
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
24/01/2024 -
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024 -
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
24/01/2024
Pages